- Differential Diagnosis
Drug Information for Intal Inhaler (cromolyn sodium inhalation aerosol) (King Pharmaceuticals, Inc.): Clinical Pharmacology
- Clinical Pharmacology
- Indications and Usage
- Adverse Reactions
- Dosage and Administration
- How Supplied
- Information for Patients
- Diseases/Conditions Related to Intal Inhaler (cromolyn sodium inhalation aerosol) (King Pharmaceuticals, Inc.)
- External Links Related to Intal Inhaler (cromolyn sodium inhalation aerosol) (King Pharmaceuticals, Inc.)
In vitro and in vivo animal studies have shown that cromolyn sodium inhibits sensitized mast cell degranulation which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of mediators from mast cells. Studies show that cromolyn sodium indirectly blocks calcium ions from entering the mast cell, thereby preventing mediator release.
Cromolyn sodium inhibits both the immediate and non-immediate bronchoconstrictive reactions to inhaled antigen. Cromolyn sodium also attenuates bronchospasm caused by exercise, toluene diisocyanate, aspirin, cold air, sulfur dioxide, and environmental pollutants, at least in some patients.
Cromolyn sodium has no intrinsic bronchodilator or antihistamine activity.
After administration of cromolyn sodium capsules by inhalation, approximately 8% of the total dose administered is absorbed and rapidly excreted unchanged, approximately equally divided between urine and bile. The remainder of the dose is either exhaled or deposited in the oropharynx, swallowed, and excreted via the alimentary tract.
- Drug Information Provided by National Library of Medicine (NLM).